«What this shows is that
increased competition among manufacturers, the
aggressive negotiations by pharmacy benefits managers, and to some extent the significant public discussion about
drug pricing and
prices have all contributed to a relatively modest level of growth in 2015,» says Murray Aitken, Executive Director of the IMS Institute.
The charges suggest that a small group of health - care firms — ones that acquire the rights to
drugs and significantly
increase their
prices — is drawing the scrutiny of regulators and prosecutors, with a possible chilling effect on
aggressive drug -
pricing strategies.